Administration of the FGF21 analogue to people suffering from obesity and type 2 diabetes caused beneficial effects on some disorders associated with diabetes; however, further studies with the analogue are needed [3, 13]. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.